Investors · September 2026

Business plan

Seven questions a serious check asks. Written for accredited investors looking at QuietScan™ — wearable pediatric brain monitoring, ages 0–5, pre-clinical.

Nickan Scientific & Innovations LLC · Pre-seed SAFE · Not an offer to sell securities.

QuietScan is designed to map active and quieter brain regions in an intended session under five minutes — no MRI, no sedation, child on a parent’s lap. QuietScan is not a treatment, not a speech therapy, and not an autism diagnostic. Intended use is monitoring and mapping for early pediatric care. The wearable has not been fabricated. This page is the thesis, not a claim of clinical results.

Seven U.S. provisional patent applications, including QuietScan and related mapping technologies.
$40,000 New Jersey CSIT Catalyst R&D voucher (AI software integration).
NIH SBIR Phase I application filed and under review.
Academic validation cooperation with Montclair State University.
Community sponsor: Mercer County Hispanic Association (MECHA) — technology-provider relationship for a pediatric access program. njmecha.org
Intended FDA 510(k) Class II pathway.

Patent filings · One-page brief

Where is money already flowing?

Spend is already committed to pediatric developmental care, imaging, and non-dilutive device R&D. The missing product is a child-safe scan that a clinic can finish without an MRI suite.

U.S. developmental disability: About 1 in 6 children ages 3–17; CDC. Care is non-discretionary and lifelong.
Autism identification: About 1 in 31 eight-year-olds; CDC ADDM. Published U.S. cost estimates sit in the hundreds of billions of dollars per year, with long-range projections in the same literature climbing toward $1 trillion.
Imaging that fails ages 0–5: MRI and EEG; Sedation for MRI can add hundreds to thousands of dollars per session, plus anesthesia staff. EEG is motion-sensitive and spatially coarse in toddlers.
Non-dilutive pediatric tech: NIH SBIR and state R&D vouchers; Nickan already holds a $40,000 NJ CSIT Catalyst voucher and has an NIH SBIR Phase I application under review.

Takeaway: demand is not the gap. The gap is a device this age group can actually complete. QuietScan is aimed at that gap.

Which problems are expensive enough to solve?

MRI in children 0–5 usually means sedation. That adds risk, cost, and an anesthesia team — and many children are simply not scanned.
EEG is long, uncomfortable, and spatially coarse. Motion in a toddler ruins the record.
Early identification is the strongest lever on outcome, yet many children are still identified after age four — after the 0–5 window QuietScan is designed for.
Published global estimates put tens of millions of children under five living with a developmental disability, most without access to advanced neuroimaging.

Delay is not abstract. Extra therapy, special education, and lost parental work compound every year a family waits for a picture of the brain. A clinic session intended in the low hundreds of dollars — if it works — is cheap next to that. Those session figures are a design target, not a price list.

What offer makes buying feel obvious?

Replace a high-risk, high-friction scan with a short, lap-based session designed for the patients current rooms fail. The buy is obvious only after bench and then clinical evidence. That is what this raise is for.

Pediatric neurology and developmental clinics

A 3D activity map in an intended session under five minutes — no MRI suite, no anesthesia calendar, no sedation protocol.

Parents

The child sits on a parent’s lap. No fasting, no recovery room, no fear of the scanner.

Payers

Intended clinic economics versus sedation-MRI: lower setting cost, lower risk, earlier monitoring — if efficacy is shown. Not a current price.

Intended use is monitoring and mapping over time — including whether a therapy is changing the map — not a one-shot autism diagnosis.

Which distribution channel can actually scale?

Phase 1

Direct clinical sales

After clearance: 50–100 U.S. pediatric neurology and autism specialty centers. Capital equipment plus software subscription. Years 1–2 post-FDA.

Phase 2

Clinic networks

Children’s-hospital systems and developmental group practices. Academic validation (Montclair) and SBIR relationships as credibility, not as a sales force.

Phase 3

Broader and remote

Portable form factor for lower-resource clinics. Scan locally, review remotely. Years 5+ and only after the U.S. clinic model works.

Intended revenue mix

Model, not current revenue. There is no product for sale.

30–40%

Device sale or lease

Helmet and electronics to clinics

25–35%

Software subscription

Mapping, delay estimation, visualization

20–30%

Per-scan supplies

Gel pads, calibration, cloud analysis

5–10%

Research licensing

Anonymized maps for pharma R&D — later

Why would people share this?

Parents and advocates. Siamak Tayebi is a father of two children on the autism spectrum and the inventor of QuietScan. The sentence that travels is concrete: see a developing brain in five minutes, on a parent’s lap, without sedation.
Clinicians and labs. A focused-ultrasound wearable for pediatric monitoring is a publishable, conference-level problem — if the bench holds.
Investors and press. Seven provisionals, a CSIT voucher, an SBIR file, and a founder who cannot shrug the problem off. That is a story. It is not a substitute for data.

Where are competitors leaving gaps?

We are not aware of a cleared wearable focused-ultrasound product for pediatric brain monitoring. That is a first-mover claim about the category, not a promise that no one is working.

MRI

Gold-standard structural imaging

Gap. Sedation for ages 0–5, suite cost, wait lists, not portable

EEG

Low cost, no ionizing radiation

Gap. Poor spatial resolution, motion artifact, hard on infants

fNIRS

Wearable and optically safe

Gap. Shallow penetration; not a focused-ultrasound map

Research fUS

High-resolution functional ultrasound in animals

Gap. Not a child-safe wearable product; often requires an open skull in the research form

Screening apps

Scalable, low cost

Gap. Behavior only. No physiological brain map

Moat, if it holds: the QuietScan helmet and mapping provisionals, a 510(k) Class II ultrasound path that is well understood, and an inventor who will not walk away. See the filings.

What breaks when revenue 10×’s?

Scale fails at manufacturing, quality, reimbursement, software, and people. Each has a mitigation that starts in this round — not after a clinic orders ten times the first batch.

Manufacturing

Now: Contract fabrication of a first wearable.
At 10×: ISO 13485 production and a dual-sourced transducer supply.
Mitigation: Supplier conversations start with the prototype, not after a 10x order.

Quality and regulatory

Now: Intended single 510(k) Class II file.
At 10×: QMS, post-market surveillance, CE / other filings.
Mitigation: Build the quality system into this raise. Regulatory hire is on the plan, not a surprise.

Reimbursement

Now: No CPT code. No human clinical data.
At 10×: Payer coverage and health-economic evidence.
Mitigation: Publish bench and then clinical outcomes early. Pilot payers only after data exist.

Software

Now: MATLAB/ANSYS simulations and CSIT-funded AI work.
At 10×: HIPAA-capable inference, retraining, audit trail.
Mitigation: Hire Python and machine-learning engineers now. Architect for clinic data before scale.

Team

Now: Founder-led. Open roles in Python and AI/ML.
At 10×: Engineering, regulatory, clinical affairs, sales.
Mitigation: Equity-heavy, mission-led hiring. Do not staff a sales team before there is a device.

The ask

Pre-seed SAFE

Company raise amount and valuation cap are in the confidential brief. This round unlocks, in order:

Helmet + electronics — First child-safe wearable array
Bench / safety — Independent testing before any clinic path
AI software — Delay estimation and 3D mapping
Regulatory / QA — 510(k) Class II intended pathway, quality system

A separate $125,000 line is the first-wearable hardware budget (60% helmet and electronics, 25% bench testing, 15% usability) — not a live public offering. What exists today: IP, MATLAB/ANSYS simulations, product renders, and CSIT-funded AI work. The wearable has not been fabricated.

Request the confidential brief One-page brief

Investigational device. Not available for sale. Not FDA cleared. Not a treatment. Nothing on this page is an offer to sell, or a solicitation of an offer to buy, securities. Offers are made only to accredited investors under a confidential brief. stayebi@nickan.ai · (609) 960-3518